CTLA4 and synovial sarcoma: Given the high incidence and homogeneous expression of CTAs in SS, we conducted a phase II study of anti-CTLA4 antibody ipilimumab as a means to increase endogenous T-cell responses against CTAs, with the hope of engendering a radiological and/or clinical response.